DW Healthcare Partners Announces Sale of LKC Technologies to AMETEK, Inc.

Rhea-AI Summary

DW Healthcare Partners announced the sale of LKC Technologies to AMETEK (NYSE: AME) on Feb. 3, 2026. LKC, a portfolio company of DWHP's Founders Fund, develops the handheld, non-invasive RETeval electroretinography (ERG) device to support retinal and optic nerve disease diagnosis. William Blair was exclusive financial advisor to LKC.

The announcement highlights LKC's 35+ years of diagnostic innovation and DWHP's three-year partnership to scale operations and raise awareness of functional retinal testing.

Positive

• Completed sale of LKC Technologies to AMETEK (NYSE: AME) announced on Feb. 3, 2026
• LKC's RETeval handheld non-invasive ERG device supports objective retinal and optic nerve assessment
• William Blair served as exclusive financial advisor to LKC Technologies

Negative

• None.

News Market Reaction

+0.53%

1 alert

+0.53% News Effect

+$276M Valuation Impact

$52.42B Market Cap

1K Volume

On the day this news was published, AME gained 0.53%, reflecting a mild positive market reaction. This price movement added approximately $276M to the company's valuation, bringing the market cap to $52.42B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Industry experience: over 35 years Partnership duration: three years

2 metrics

Industry experience over 35 years LKC’s history pioneering visual electrophysiology diagnostics

Partnership duration three years Period LKC was supported by DW Healthcare Partners

Market Reality Check

Price: $229.76 Vol: Volume 2,214,176 is 1.67x...

high vol

$229.76 Last Close

Volume Volume 2,214,176 is 1.67x the 20-day average of 1,324,101 shares, indicating elevated interest ahead of this announcement. high

Technical Shares trade above the 200-day MA of 188.4, reflecting a pre-existing upward trend into this deal news.

Peers on Argus

Key peers such as ROK (+2.18%), IR (+3.31%), XYL (+1.45%), OTIS (+0.85%), and IT...

Key peers such as ROK (+2.18%), IR (+3.31%), XYL (+1.45%), OTIS (+0.85%), and ITW (+1.12%) were up, but momentum scanners did not flag a coordinated sector move, suggesting this headline is more company-specific.

Historical Context

5 past events · Latest: Jan 15 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 15	Earnings call notice	Positive	+1.9%	Announced Q4 2025 earnings release date and reiterated growth model focus.
Dec 18	Product launch	Positive	+1.0%	Introduced SkyBitz SmartTank ST705 radar monitor with long battery life and accuracy.
Nov 11	Sustainability report	Positive	-0.2%	Released 2025 sustainability report with substantial emissions‑reduction progress.
Nov 07	Dividend declaration	Positive	-0.5%	Declared regular <b>$0.31</b> quarterly dividend and reiterated growth strategy.
Nov 07	Leadership changes	Neutral	-0.5%	Announced internal finance leadership succession and retirement of long‑tenured executive.

Pattern Detected

Product and earnings-related updates have often coincided with positive moves, while sustainability and dividend announcements previously saw mild negative reactions.

Recent Company History

Over the last few months, AMETEK has highlighted its scale of ~$7.5 billion in annual sales, ongoing strategic acquisitions, and a growth model targeting double‑digit EPS growth. Prior news included an upcoming Q4 2025 earnings release (Feb 3, 2026), new product launches such as the SkyBitz ST705 monitor, sustainability targets with a 33% emissions‑intensity reduction, dividend continuity at $0.31 per share, and finance leadership succession—providing context for this additional M&A-focused announcement.

Market Pulse Summary

This announcement adds another strategic acquisition to AMETEK’s history of expanding through specia...

Analysis

This announcement adds another strategic acquisition to AMETEK’s history of expanding through specialized technologies, in this case visual electrophysiology and electroretinography for retinal and optic nerve disease assessment. Recent news has emphasized scale of ~$7.5 billion in annual sales, product innovation, and emissions‑reduction progress. Investors may watch upcoming earnings for details on purchase economics, integration plans, and how this target fits within AMETEK’s broader operational and returns-focused growth framework.

Key Terms

visual electrophysiology, electroretinography (ERG), optic nerve

3 terms

visual electrophysiology medical

"As leaders in the world of visual electrophysiology, LKC Technologies..."

Visual electrophysiology is a set of clinical tests that measure the electrical responses generated by the eye and visual pathways when exposed to light or patterns, like checking the wiring and output of a lamp and its circuit. For investors, these tests matter because they provide objective evidence of how well a vision therapy, device, or drug is working, are often used as regulatory endpoints in trials, and can affect product approval, market adoption, and reimbursement.

electroretinography (ERG) medical

"handheld, non-invasive electroretinography (ERG) device, the RETeval, delivers..."

Electroretinography (ERG) is a clinical test that measures the electrical signals generated by the retina when it is exposed to light, similar to checking the wiring in a camera to see if the image sensor is working. For investors, ERG results matter because they are used as objective evidence in clinical trials and regulatory reviews to show whether a drug, gene therapy, or medical device is improving retinal function, which can affect approval prospects and market value.

optic nerve medical

"supports the diagnosis and management of retinal and optic nerve diseases."

The optic nerve is the bundle of nerve fibers that carries visual signals from the back of the eye to the brain, like a cable transmitting a camera’s images to a computer. It matters to investors because diseases, injuries, diagnostic tests and treatments that affect the optic nerve can drive markets for drugs, surgical devices and imaging tools, influence clinical trial outcomes and regulatory decisions, and therefore affect company value and revenue prospects.

AI-generated analysis. Not financial advice.

TORONTO and PARK CITY, Utah, Feb. 3, 2026 /PRNewswire/ -- DW Healthcare Partners ("DWHP"), a healthcare-focused private equity firm, today announces the sale of LKC Technologies to AMETEK, Inc. (NYSE: AME).

As leaders in the world of visual electrophysiology, LKC Technologies, a portfolio company of DW Healthcare Partners' Founders Fund, is dedicated to preserving sight by expanding access to objective functional retinal assessments. For over 35 years, LKC has pioneered innovations in diagnostic technology, transforming complex visual electrophysiology into intuitive, accessible solutions for clinicians and researchers worldwide.

Building on decades of industry leadership, the company's handheld, non-invasive electroretinography (ERG) device, the RETeval, delivers reliable, objective data that supports the diagnosis and management of retinal and optic nerve diseases. Anchored by a mission to improve patient outcomes, LKC empowers eye care professionals with innovative tools and quality customer service to advance clinical care and accelerate research. "We would like to thank the team at DWHP for their tremendous support over the last three years." stated Dina Dubey, CEO of LKC Technologies. "They have been wonderful partners and have made significant contributions to the incredible growth and success of the company."

"LKC Technologies represents exactly the kind of opportunity we look for—a company with a deeply rooted mission and a product that fundamentally changes patient outcomes," said Gabe Becher, Managing Director at DW Healthcare Partners. "Over the course of our partnership, we worked closely with the exceptional team at LKC to scale their operations and raise awareness of functional retinal testing in detecting sight-threatening diseases early. We are incredibly proud of what the company achieved and look forward to watching LKC continue to flourish."

William Blair served as exclusive financial advisor to LKC Technologies.

About DW Healthcare Partners

DW Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. The firm manages six funds with over $2.7 billion in assets under management, as of December 31, 2025. DW Healthcare Partners is led by seasoned executives with more than 155 years of combined healthcare industry and investing experience. The firm provides capital, strategic guidance, and acquisition support to help mid-stage companies grow and scale. For more information, please visit: dwhp.com

Media Contact: acc@dwhp.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dw-healthcare-partners-announces-sale-of-lkc-technologies-to-ametek-inc-302677140.html

SOURCE DW Healthcare Partners

FAQ

What did DW Healthcare Partners announce about LKC Technologies on Feb. 3, 2026?

DW Healthcare Partners announced the sale of LKC Technologies to AMETEK (NYSE: AME). According to DW Healthcare Partners, the transaction transfers ownership of LKC, a portfolio company of its Founders Fund, after a three-year partnership to scale the business.

What product does LKC Technologies make and why is it important for AMETEK (AME)?

LKC produces the handheld RETeval electroretinography device used in retinal and optic nerve diagnostics. According to LKC, RETeval delivers reliable, objective data to support diagnosis and management of sight-threatening diseases for clinicians and researchers.

Who advised LKC Technologies in the sale to AMETEK (NYSE: AME)?

William Blair served as exclusive financial advisor to LKC Technologies in the transaction. According to the announcement, William Blair advised on the sale process and execution for LKC and its stakeholders.

How long has LKC Technologies been developing visual electrophysiology tools before the AMETEK sale?

LKC Technologies has more than 35 years of experience in visual electrophysiology. According to the company, it has pioneered diagnostic innovations to make complex electrophysiology testing more intuitive and accessible worldwide.

What role did DW Healthcare Partners play in LKC Technologies before the sale to AMETEK (AME)?

DW Healthcare Partners was an owner through its Founders Fund and partnered with LKC for three years. According to DW Healthcare Partners, it helped scale operations and raise awareness of functional retinal testing during that period.